| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.CIR.0000124061.78478.94 |
| P698 | PubMed publication ID | 15023892 |
| P2093 | author name string | Mark E Cooper | |
| Markus Lassila | |||
| Zemin Cao | |||
| Riccardo Candido | |||
| Terri J Allen | |||
| Vicki Thallas | |||
| Karin A Jandeleit-Dahm | |||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | atherosclerosis | Q12252367 |
| P304 | page(s) | 1536-1542 | |
| P577 | publication date | 2004-03-15 | |
| P1433 | published in | Circulation | Q578091 |
| P1476 | title | Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis | |
| P478 | volume | 109 |
| Q41275103 | (Pro)renin receptor-mediated signal transduction and tissue renin-angiotensin system contribute to diabetes-induced retinal inflammation |
| Q36885183 | AT1-receptor-deficiency induced atheroprotection in diabetic mice is partially mediated via PPARγ |
| Q36012843 | Actions of calcium channel blockers on vascular proteoglycan synthesis: relationship to atherosclerosis |
| Q37041493 | Amlodipine attenuates oxidative stress in the heart and blood of high-cholesterol diet rabbits. |
| Q37308953 | Amlodipine reduces AngII-induced aortic aneurysms and atherosclerosis in hypercholesterolemic mice |
| Q35569854 | An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction |
| Q40041537 | Angiotensin II Blockade and Total Cardiovascular Risk : Beyond Blood Pressure Reduction |
| Q37391675 | Angiotensin II Promotes the Development of Carotid Atherosclerosis in Type 2 Diabetes Patients via Regulating the T Cells Activities: A Cohort Study |
| Q35116630 | Angiotensin II modulates interleukin-1β-induced inflammatory gene expression in vascular smooth muscle cells via interfering with ERK-NF-κB crosstalk |
| Q46103013 | Angiotensin II subtype 2 receptor blockade and deficiency attenuate the development of atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes. |
| Q42554373 | Angiotensin-Converting Enzyme 2 (ACE2) Is a Key Modulator of the Renin Angiotensin System in Health and Disease |
| Q51280766 | Angiotensin-converting enzyme 2 amplification limited to the circulation does not protect mice from development of diabetic nephropathy. |
| Q34355358 | Apolipoprotein A-I mimetic peptides prevent atherosclerosis development and reduce plaque inflammation in a murine model of diabetes |
| Q43012329 | Are angiotensin converting enzyme inhibitors beneficial in patients with aortic stenosis? |
| Q46335942 | Association of dietary sodium intake with atherogenesis in experimental diabetes and with cardiovascular disease in patients with Type 1 diabetes |
| Q37518158 | Calcium channel regulation in vascular smooth muscle cells: synergistic effects of statins and calcium channel blockers |
| Q43257049 | Cell division autoantigen 1 plays a profibrotic role by modulating downstream signalling of TGF-beta in a murine diabetic model of atherosclerosis |
| Q36292056 | Cognition and Hemodynamics |
| Q34550600 | Combined NOX1/4 inhibition with GKT137831 in mice provides dose-dependent reno- and atheroprotection even in established micro- and macrovascular disease |
| Q36025434 | Comparative effects of different modes of renin angiotensin system inhibition on hypercholesterolaemia-induced atherosclerosis. |
| Q37404651 | Contributions of leukocyte angiotensin-converting enzyme to development of atherosclerosis |
| Q54397160 | Delayed intervention with AGE inhibitors attenuates the progression of diabetes-accelerated atherosclerosis in diabetic apolipoprotein E knockout mice. |
| Q35923732 | Deletion of angiotensin-converting enzyme 2 exacerbates renal inflammation and injury in apolipoprotein E-deficient mice through modulation of the nephrin and TNF-alpha-TNFRSF1A signaling |
| Q39420474 | Deletion of angiotensin-converting enzyme 2 promotes the development of atherosclerosis and arterial neointima formation |
| Q34350546 | Diabetes alters activation and repression of pro- and anti-inflammatory signaling pathways in the vasculature |
| Q37486465 | Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions |
| Q36744061 | Diabetes reduces aortic endothelial gap junctions in ApoE-deficient mice: simvastatin exacerbates the reduction |
| Q36599243 | Differential effects of dietary sodium intake on blood pressure and atherosclerosis in hypercholesterolemic mice. |
| Q60921775 | Effects of Irbesartan Pretreatment on Pancreatic -Cell Apoptosis in STZ-Induced Acute Prediabetic Mice |
| Q45195936 | Effects of direct renin inhibition on atherosclerotic biomarkers in patients with stable coronary artery disease and type 2 diabetes mellitus. |
| Q86207080 | Effects of telmisartan or amlodipine monotherapy versus telmisartan/amlodipine combination therapy on vascular dysfunction and oxidative stress in diabetic rats |
| Q36766914 | Endothelial effects of antihypertensive treatment: focus on irbesartan |
| Q43283572 | Expression of constitutively active cGMP-dependent protein kinase inhibits glucose-induced vascular smooth muscle cell proliferation |
| Q46931630 | Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation |
| Q40549729 | Ginkgo suppresses atherosclerosis through downregulating the expression of connexin 43 in rabbits |
| Q24608214 | Glycation of LDL by methylglyoxal increases arterial atherogenicity: a possible contributor to increased risk of cardiovascular disease in diabetes |
| Q36072601 | How to best manage glycemia and non-glycemia during the time of acute myocardial infarction |
| Q37163462 | Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail |
| Q57182351 | Linking diabetes and atherosclerosis |
| Q38775422 | MRI detection of endothelial cell inflammation using targeted superparamagnetic particles of iron oxide (SPIO). |
| Q36222092 | Monocyte Chemoattractant Protein 1 (MCP-1) in obesity and diabetes |
| Q89967822 | Monocytes and Macrophages as Protagonists in Vascular Complications of Diabetes |
| Q26830607 | Nitric oxide, oxidative stress, and p66Shc interplay in diabetic endothelial dysfunction |
| Q37990618 | Novel pathways and therapies in experimental diabetic atherosclerosis |
| Q36688756 | Oral direct renin inhibition: premise, promise, and potential limitations of a new antihypertensive drug |
| Q60952201 | Oxidative Stress in Cardiac Tissue of Patients Undergoing Coronary Artery Bypass Graft Surgery: The Effects of Overweight and Obesity |
| Q36444975 | PPAR Agonists and Cardiovascular Disease in Diabetes |
| Q36346487 | Pharmacological basis of different targets for the treatment of atherosclerosis. |
| Q57182331 | Prevention of accelerated atherosclerosis by AT1 receptor blockade in experimental renal failure |
| Q36842628 | Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes |
| Q36458652 | Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice |
| Q35141843 | Role of Cell Division Autoantigen 1 (CDA1) in Cell Proliferation and Fibrosis |
| Q37091107 | The AGE/RAGE axis in diabetes-accelerated atherosclerosis. |
| Q36405350 | The Establishment and Characteristics of Rat Model of Atherosclerosis Induced by Hyperuricemia |
| Q46506824 | The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation |
| Q38771740 | The angiotensin II type 2 receptor agonist Compound 21 is protective in experimental diabetes-associated atherosclerosis. |
| Q43253718 | The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice. |
| Q38200957 | The pathobiology of diabetic vascular complications--cardiovascular and kidney disease |
| Q36018270 | The protective effects of oral low-dose quercetin on diabetic nephropathy in hypercholesterolemic mice. |
| Q36532932 | The role of type 1 angiotensin receptors on T lymphocytes in cardiovascular and renal diseases |
| Q38052410 | Therapeutic role of toll-like receptor modification in cardiovascular dysfunction |
| Q90366910 | Transactivation of RAGE mediates angiotensin-induced inflammation and atherogenesis |
| Q28577025 | Treatment with low-dose atorvastatin, losartan, and their combination increases expression of vasoactive-related genes in rat aortas |
| Q28077454 | Update on RAAS Modulation for the Treatment of Diabetic Cardiovascular Disease |
| Q80968903 | Upregulation of the ligand-RAGE pathway via the angiotensin II type I receptor is essential in the pathogenesis of diabetic atherosclerosis |
| Q46049450 | Valsartan preconditioning protects against myocardial ischemia-reperfusion injury through TLR4/NF-kappaB signaling pathway |
| Q36861584 | Vascular benefits of angiotensin receptor blockers |
| Q82770382 | [The renin-angiotensin system in hypertension and in cardiovascular and renal diseases: highlights of the World Congress of Nephrology 2009]] |
| Q28582087 | cAbl tyrosine kinase mediates reactive oxygen species- and caveolin-dependent AT1 receptor signaling in vascular smooth muscle: role in vascular hypertrophy |
Search more.